About Crux Biomedical
Crux Biomedical is a Healthcare company based in Menlo Park (United States) founded in 2004, and was acquired by Volcano in December 2012. Retrievable vena cava filters are developed to prevent pulmonary emboli. Crux Biomedical has raised $8 million across 1 funding round from investors including Volcano and Alloy Ventures. Its focus areas include Life Sciences, Cardiac and Vascular Disorders, Medical Devices and Therapeutic Devices. Its competitors include Aria CV, Adient Medical and Bellerophon Therapeutics; 2 of its 3 listed competitors have raised funding.
Company details
Crux Biomedical developed a vena cava filter - a type of retrievable vascular filter, that is implanted by interventional radiologists or vascular surgeons into the vena cava to presumably prevent life-threatening pulmonary emboli. USP is a unique self-centering helical design and can be deployed and retrieved through jugular or femoral vessels. Received CE Mark in December 2011 and 510(k) clearance in July 2012. Crux was acquired by Volcano in 2012.
- Headquarters Menlo Park, United States
- Stage Acquired
- SectorsHealthcare
- Website cruxbiomedical.com
- Social LinkedIn
- Acquired by Volcano (Dec 2012)
Funding Insights of Crux Biomedical
Crux Biomedical has successfully raised a total of $8M through 1 strategic funding round. The most recent funding activity was a Series B round of $8 million completed in January 2009. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $8M
- Total Rounds 1
- Last Round Series B — $8M
- First Round $8M
(Jan 2009)
- Investors Count 1
All 1 funding rounds of Crux Biomedical with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2009 | $8M | Series B | – | – |
2 investors in total: 2 institutional.
Investors in Crux Biomedical
Crux Biomedical has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Volcano and Alloy Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early stage venture capital firm investing in the US | alloyventures.com | Palo Alto, United States | ||
Products for vascular imaging and peripheral therapeutics are provided. | 2000 | volcanocorp.com | San Diego, United States |
Investor details for Crux Biomedical
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Crux Biomedical
3 dated milestones of Crux Biomedical across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Crux Biomedical is founded.
- Funding First funding round of $8.0M.
- Exit Acquired by Volcano.
Competitors of Crux Biomedical
Crux Biomedical has 3 listed competitors in our database, 2 of them funded. They include Aria CV, Adient Medical and Bellerophon Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| ariacv.com | 2010 | Saint Paul, United States | $44.98M | 17 | Device for pulmonary hypertension | |
| adientmedical.com | 2012 | Pearland, United States | $19.43M | 6,421 | Bioabsorbable medical devices are developed for pulmonary embolism prevention. | |
| bellerophon.com | 2014 | Hampton, United States | 18 | Drug-device therapies for pulmonary hypertension are developed. |
Detailed competitors of Crux Biomedical
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Cardiac and Vascular Disorders
3 companies that operate in the same segment as Crux Biomedical (Cardiac and Vascular Disorders) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Gene-editing therapies for coronary artery disease are developed. | 2018 | Cambridge, Massachusetts, United States | USD 215.5 M | 255 | ||
Cardiac monitoring devices and applications are provided for heart health. | 2010 | Mountain View, California, United States | USD 114.38 M | USD 6.18 M | 67 | |
Therapies for lowering low-density lipoprotein cholesterol levels are developed. | 1998 | Ann Arbor, Michigan, United States | USD 129.7 M | USD 332.31 M | 304 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Crux Biomedical
Complete news archive for Crux Biomedical
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Crux Biomedical
Crux Biomedical was founded in 2004 and raised its 1st funding round 5 years after it was founded.
Crux Biomedical is headquartered in Menlo Park, United States. It is registered at Menlo Park, California, United States.
Crux Biomedical is a funded company, having raised a total of $8M across 1 funding round to date. The company's 1st funding round was a Series B of $8M, raised on Jan 2009.
Crux Biomedical developed a vena cava filter - a type of retrievable vascular filter, that is implanted by interventional radiologists or vascular surgeons into the vena cava to presumably prevent life-threatening pulmonary emboli. USP is a unique self-centering helical design and can be deployed and retrieved through jugular or femoral vessels. Received CE Mark in December 2011 and 510(k) clearance in July 2012. Crux was acquired by Volcano in 2012.
Crux Biomedical's top competitors include Aria CV, Adient Medical and Bellerophon Therapeutics.
Crux Biomedical has 2 investors. Key investors include Volcano, and Alloy Ventures.
Yes. Crux Biomedical was acquired by Volcano in December 2012.